Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | DUT | P33316 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24205032 | 1.00 | NAAA (0.54) | NAAADUTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL25368590 | 1.00 | NAAA (0.54) | NAAADUTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL913371 | 1.00 | NAAA (0.54) | NAAADUTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL913206 | 0.98 | DUT (0.55) | NAAADUTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3079985 | 0.93 | DUT (0.56) | NAAADUTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2983407 | 0.85 | ALDH1A1 (0.57) | DUTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL7181572 | 0.83 | DUT (0.54) | NAAADUTL3MBTL1PDE3A | |
| SCHEMBL2215255 | 0.83 | DUT (0.54) | NAAADUTL3MBTL1PDE3A | |
| SCHEMBL17372138 | 0.83 | DUT (0.55) | NAAADUT | |
| SCHEMBL25433467 | 0.82 | GPR84 (0.56) | NAAADUTLMNAPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110603265-B | Compositions and methods for immunotherapy of cancer with anti-mesothelin | 莱蒂恩技术公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111741757-B | Compositions and methods for treating cancer with anti-ROR 1 immunotherapy | 莱蒂恩技术公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116829581-A | Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy | 莱蒂恩技术公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116801898-A | Compositions and methods for treating cancer with anti-CD 19/CD22 immunotherapy | 莱蒂恩技术公司 | 2023-09-22 | — | — | CN | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | NAAA 1271/4885DUT 1/4885ALDH1A1 1723/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | NAAA 1298/4885DUT 1/4885ALDH1A1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.